
When an electrical current is delivered to one of the chip’s tiny reservoirs, a single does of therapeutics releases into the body.
Image: MIT/Microchips Biotech
After extensive research, MIT engineers are on their way to commercializing microchips that release therapeutics inside of the body.
The implantable microchip-based device has the potential to outpace injections and conventional pills, changing the landscape of health care and treatment as we know it.
A startup stemming from MIT, Microchips Biotech, developed this technology and has partnered with Teva Pharmaceutical to get these chips into the market. Teva Pharmaceutical is a giant in the industry and the world’s largest producer of generic drugs.
This from MIT:
The microchips consist of hundreds of pinhead-sized reservoirs, each capped with a metal membrane, that store tiny doses of therapeutics or chemicals. An electric current delivered by the device removes the membrane, releasing a single dose. The device can be programmed wirelessly to release individual doses for up to 16 years to treat, for example, diabetes, cancer, multiple sclerosis, and osteoporosis.








